# A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

> **NCT04750278** · PHASE2,PHASE3 · TERMINATED · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 90 (actual)

## Conditions studied

- Severe to Critical COVID 19 With Associated ARDS

## Interventions

- **DRUG:** FP-025 100 mg
- **DRUG:** FP-025 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04750278
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-06
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-18
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Study stopped at interim analysis point, due to lack of study subjects to recruit.
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04750278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04750278, "A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04750278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*